journal
https://read.qxmd.com/read/38640466/mtor-signaling-promotes-rapid-m6a-mrna-methylation-to-regulate-nk-cell-activation-and-effector-functions
#1
JOURNAL ARTICLE
Meng Meng, Zhaoyang Zhong, Liang Song, Zhaohui Zhang, Xiaofeng Yin, Xiqiang Xie, Lei Tian, Wei Wu, Yao Yang, Yafei Deng, Hongyan Peng, Shuting Wu, Guanghe Ran, Yuqing Lin, Qiangqiang Lai, Qinghua Bi, Fulin Yan, Yan Ji, Yang Wang, Xiaohui Li, Ping Yi, Jianhua Yu, Youcai Deng
Natural killer (NK) cells can be rapidly activated in response to cytokines during host defense against malignant cells or viral infection. However, it remains unclear what mechanisms precisely and rapidly regulate the expression of the numerous genes involved in activating NK cells. In this study, we discovered that NK-cell N6-methyladenosine (m6A) methylation levels were rapidly upregulated upon short-term NK-cell activation and were repressed in the tumor microenvironment. Deficiency of methyltransferase-like 3 (METTL3) or METTL14 moderately influenced NK-cell homeostasis, while double knockout of METTL3/14 significantly impacted NK-cell homeostasis, maturation, and antitumor immunity...
April 19, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38631025/melanoma-clonal-heterogeneity-leads-to-secondary-resistance-after-adoptive-cell-therapy-with-tumor-infiltrating-lymphocytes
#2
JOURNAL ARTICLE
David König, Michael Sandholzer, Sarp Uzun, Andreas Zingg, Reto Ritschard, Helen Thut, Katharina Glatz, Elisabeth A Kappos, Dirk J Schaefer, Christoph Kettelhack, Jakob R Passweg, Andreas Holbro, Katharina Baur, Michael Medinger, Andreas Buser, Didier Lardinois, Lukas T Jeker, Nina Khanna, Frank Stenner, Benjamin Kasenda, Krisztian Homicsko, Matthias Matter, Natalia Rodrigues Mantuano, Alfred Zippelius, Heinz Läubli
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is effective in melanoma patients, although long-term responses seem restricted to patients who have complete remissions. Many patients develop secondary resistance to TIL-ACT but the involved mechanisms are unclear. Here, we describe a case of secondary resistance to TIL-ACT likely due to intratumoral heterogeneity and selection of a resistant tumor cell clone by the transferred T cells. To our knowledge, this is the first case of clonal selection of a pre-existing non-dominant tumor cell clone and it demonstrates a mechanism involved in secondary resistance to TIL-ACT that could potentially change current clinical practice, because it advocates for T-cell collection from multiple tumor sites and analysis of tumor heterogeneity before the treatment with TIL-ACT...
April 17, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38631019/orchestrated-codelivery-of-peptide-antigen-and-adjuvant-to-antigen-presenting-cells-by-using-an-engineered-chimeric-peptide-enhances-antitumor-t-cell-immunity
#3
JOURNAL ARTICLE
Haifeng Pan, Siyuan Yu, Haoyun Zhuang, Han Yang, Jinlu Jiang, Haihui Yang, Shuling Ren, Guoxing Luo, Xuan Yu, Shuping Chen, Yanhua Lin, Roufang Sheng, Shiyin Zhang, Quan Yuan, Chenghao Huang, Tianying Zhang, Tingdong Li, Shengxiang Ge, Jun Zhang, Ningshao Xia
The intrinsic pharmacokinetic limitations of traditional peptide-based cancer vaccines hamper effective cross-presentation and codelivery of antigens and adjuvants, which are crucial for inducing robust antitumor CD8+ T-cell responses. Here, we report the development of a versatile strategy that simultaneously addresses the different pharmacokinetic challenges of soluble subunit vaccines composed of antigens and CpG to modulate vaccine efficacy via translating an engineered chimeric peptide, eTAT, as an intramolecular adjuvant...
April 17, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38630891/sirt3-negatively-regulates-tfh-cell-differentiation-in-cancer
#4
JOURNAL ARTICLE
Yueru Hou, Yejin Cao, Ying He, Lin Dong, Longhao Zhao, Yingjie Dong, Ruiying Niu, Yujing Bi, Guangwei Liu
Follicular helper T (TFH) cells are essential for inducing germinal center (GC) reactions to mediate humoral adaptive immunity in tumors, but the mechanisms underlying TFH cell differentiation remain unclear. Here, we found that the metabolism sensor sirtuin 3 (SIRT3) is critical for TFH cell differentiation and GC formation during tumor and viral infection. SIRT3 deficiency in CD4+ T cells intrinsically enhanced TFH cell differentiation and GC reactions during tumor and virus infection. Mechanistically, damaged oxidative phosphorylation (OXPHOS) compensatively triggered the NAD+-glycolysis pathway to provide a cellular energy supply, which was necessary for SIRT3 deficiency-induced TFH cell differentiation...
April 17, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38573707/the-neo-open-reading-frame-peptides-that-comprise-the-tumor-framome-are-a-rich-source-of-neoantigens-for-cancer-immunotherapy
#5
JOURNAL ARTICLE
Michael V Martin, Salvador Aguilar-Rosas, Katka Franke, Mark Pieterse, Jamie van Langelaar, Renee Rce Schreurs, Maarten F Bijlsma, Marc G Besselink, Jan Koster, Wim Timens, Mustafa Khasraw, David M Ashley, Stephen T Keir, Christian H Ottensmeier, Emma V King, Joanne Verheij, Cynthia Waasdorp, Peter J M Valk, Sem Ag Engels, Ellen Oostenbach, Jip T van Dinter, Damon A Hofman, Juk Yee Mok, Wim J E van Esch, Hanneke Wilmink, Kim Monkhorst, Henk M W Verheul, Dennis Poel, T Jeroen N Hiltermann, Léon C van Kempen, Harry Jm Groen, Joachim G J V Aerts, Sebastiaan van Heesch, Bob Lowenberg, Ronald Plasterk, Wigard P Kloosterman
Identification of immunogenic cancer neoantigens as targets for therapy is challenging. Here, we integrate cancer whole genome and long-read transcript sequencing to identify the collection of novel open reading frame peptides (NOPs) expressed in tumors, termed the framome. NOPs represent tumor-specific peptides that are different from wild-type proteins and may be strongly immunogenic. We describe an uncharacterized class of hidden NOPs, which derive from structural genomic variants involving an upstream protein coding gene driving expression and translation of non-coding regions of the genome downstream of a rearrangement breakpoint...
April 4, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38572963/small-extracellular-vesicle-pir-hsa-30937-derived-from-pancreatic-neuroendocrine-neoplasms-upregulates-cd276-in-macrophages-to-promote-immune-evasion
#6
JOURNAL ARTICLE
Yuan Zhong, Ye Tian, Yan Wang, Jian'an Bai, Qin Long, Lijun Yan, Zhihui Gong, Wei Gao, Qiyun Tang
The role of PIWI-interacting RNAs (piRNAs) in small extracellular vesicles (sEV) derived from pancreatic neuroendocrine neoplasms (PNEN) in the tumor microenvironment (TME) remains unexplored. We used multiplex immunohistochemistry (mIHC) to analyze the expression of CD68, CD276 (B7H3) and CD3 on PNEN. CD276+ tumor-associated macrophages (TAMs) were more abundant in tumor tissues than nontumor tissues and negatively correlated with T-cell infiltration. Serum sEV piRNA sequencing was performed to identify piRNAs enriched in PNEN patients...
April 3, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38572955/preclinical-evaluation-of-off-the-shelf-pd-l1-human-natural-killer-cells-secreting-il15-to-treat-non-small-cell-lung-cancer
#7
JOURNAL ARTICLE
Ting Lu, Rui Ma, Anthony G Mansour, Christian Bustillos, Zhiyao Li, Zhenlong Li, Shoubao Ma, Kun-Yu Teng, Hanyu Chen, Jianying Zhang, Miguel A Villalona-Calero, Michael A Caligiuri, Jianhua Yu
We described previously a human natural killer (NK) cell population that upregulates PD-L1 expression upon recognizing and reacting to tumor cells or exposure to a combination of IL12, IL18 and IL15. Here, to investigate the safety and efficacy of tumor-reactive and cytokine-activated (TRACK) NK cells, human NK cells from umbilical cord blood were expanded, transduced with a retroviral vector encoding soluble (s) IL15, and further cytokine activated to induce PD-L1 expression. Our results show cryopreserved and thawed sIL15_TRACK NK cells had significantly improved cytotoxicity against non-small cell lung cancer (NSCLC) in vitro when compared to non-transduced (NT) NK cells, PD-L1+ NK cells lacking sIL15 expression (NT_TRACK NK), or NK cells expressing sIL15 without further cytokine activation (sIL15 NK cells)...
April 3, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38568780/stressing-the-role-of-ccl3-in-reversing-the-immunosuppressive-microenvironment-in-gliomas
#8
JOURNAL ARTICLE
Xiaoteng Cui, Chunsheng Kang
Patients with gliomas often experience mental health problems, such as depression and anxiety, that lead to worsening tumor progression and shortened survival. In this issue, Wang and colleagues report a novel mechanism underlying this, finding that chronic stress reduces secretion of the chemokine CCL3, which leads to an immunosuppressive glioma microenvironment. CCL3 administration enhances the infiltration of antitumor immune cells, providing rationale for a potential new therapeutic approach. See related article by Wang et al...
April 2, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38568775/interactions-between-mdscs-and-the-autonomic-nervous-system-opportunities-and-challenges-in-cancer-neuroscience
#9
JOURNAL ARTICLE
Lin-Zhen Shu, Yi-Dan Ding, Jin-Yao Zhang, Rui-Shan He, Li Xiao, Bing-Xing Pan, Huan Deng
Myeloid-derived suppressor cells (MDSC) are a population of heterogeneous immune cells that are involved in precancerous conditions and neoplasms. The autonomic nervous system (ANS), which is composed of the sympathetic nervous system and the parasympathetic nervous system, is an important component of the tumor microenvironment that responds to changes in the internal and external environment mainly through adrenergic and cholinergic signaling. An abnormal increase of autonomic nerve density has been associated with cancer progression...
April 2, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38592331/unleashing-natural-il18-activity-using-an-anti-il18bp-blocker-induces-potent-immune-stimulation-and-antitumor-effects
#10
JOURNAL ARTICLE
Assaf Menachem, Zoya Alteber, Gady Cojocaru, Tal Fridman Kfir, Dan Blat, Olga Leiderman, Moran Galperin, Lital Sever, Nadav Cohen, Keren Cohen, Roy Z Granit, Sandra Vols, Masha Frenkel, Liron Soffer, Karin Meyer, Keren Menachem, Hadas Galon Tilleman, Dina Morein, Itamar Borukhov, Amir Toporik, Michal Perpinial Shahor, Evgeny Tatirovsky, Aviram Mizrachi, Adva Levy-Barda, Eran Sadot, Yulia Strenov, Ram Eitan, Ariella Jakobson-Setton, Natalia Yanichkin, Pierre Ferre, Eran Ophir
Recombinant cytokines have limited anticancer efficacy mostly due to a narrow therapeutic window and systemic adverse effects. IL18 is an inflammasome-induced proinflammatory cytokine, which enhances T- and NK-cell activity and stimulates IFNγ production. The activity of IL18 is naturally blocked by a high-affinity endogenous binding protein (IL18BP). IL18BP is induced in the tumor microenvironment (TME) in response to IFNγ upregulation in a negative feedback mechanism. In this study, we found that IL18 is upregulated in the TME compared with the periphery across multiple human tumors and most of it is bound to IL18BP...
April 1, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38588410/pvrl2-suppresses-antitumor-immunity-through-pvrig-and-tigit-independent-pathways
#11
JOURNAL ARTICLE
Jiuling Yang, Li Wang, James R Byrnes, Lisa L Kirkemo, Hannah Driks, Cassandra D Belair, Oscar A Aguilar, Lewis L Lanier, James A Wells, Lawrence Fong, Robert Blelloch
Poliovirus receptor-related 2 (PVRL2, also known as nectin-2 or CD112) is believed to act as an immune checkpoint protein in cancer; however, most insight into its role is inferred from studies on its known receptor, poliovirus receptor (PVR)-related immunoglobulin domain protein (PVRIG, also known as CD112R). Here, we study PVRL2 itself. PVRL2 levels were found to be high in tumor cells and tumor-derived exosomes. Deletion of PVRL2 in multiple syngeneic mouse models of cancer showed a dramatic reduction in tumor growth that was immune dependent...
April 1, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38563577/engineering-cd3-cd137-dual-specificity-into-a-dll3-targeted-t-cell-engager-enhances-t-cell-infiltration-and-efficacy-against-small-cell-lung-cancer
#12
JOURNAL ARTICLE
Hirofumi Mikami, Shu Feng, Yutaka Matsuda, Shinya Ishii, Sotaro Naoi, Yumiko Azuma, Hiroaki Nagano, Kentaro Asanuma, Yoko Kayukawa, Toshiaki Tsunenari, Shogo Kamikawaji, Ryutaro Iwabuchi, Junko Shinozuka, Masaki Yamazaki, Haruka Kuroi, Samantha Shu Wen Ho, Siok Wan Gan, Priyanka Chichili, Chai Ling Pang, Chiew Ying Yeo, Shun Shimizu, Naoka Hironiwa, Yasuko Kinoshita, Yuichiro Shimizu, Akihisa Sakamoto, Masaru Muraoka, Noriyuki Takahashi, Tatsuya Kawa, Hirotake Shiraiwa, Futa Mimoto, Kenji Kashima, Mika Kamata-Sakurai, Shumpei Ishikawa, Hiroyuki Aburatani, Takehisa Kitazawa, Tomoyuki Igawa
Small-cell lung cancer (SCLC) is an aggressive cancer for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives for ICI-resistant tumors, but not all patients with SCLC are responsive. Herein, to integrate CD137 costimulatory function into a T-cell engager format and thereby augment therapeutic efficacy, we generated a CD3/CD137 dual-specific Fab and engineered a DLL3-targeted trispecific antibody (DLL3 trispecific). The CD3/CD137 dual-specific Fab was generated to competitively bind to CD3 and CD137 to prevent DLL3-independent cross-linking of CD3 and CD137, which could lead to systemic T-cell activation...
April 1, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38557780/living-in-syn-t-cell-antigen-identification-based-on-synapse-sequencing
#13
JOURNAL ARTICLE
Venkata Krishna Kanth Makani, Alok V Joglekar
The pivotal role of T cell responses has been well studied in both protective and destructive scenarios. T cells recognize peptide epitopes presented on Human Leukocyte Antigens (HLA) through their surface T cell receptors (TCR). Advances in single-cell RNA sequencing have identified millions of TCRs, but only a minuscule fraction of them have known epitopes. Recently, cell-based T cell antigen discovery platforms have emerged onto the landscape. Here, Jin and colleagues, report a novel antigen discovery platform called Tsyn-seq that relies on sequencing TCR-peptide-HLA-induced synapses for genome-wide epitope screening...
March 29, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38552171/randomized-phase-ii-study-evaluating-the-addition-of-pembrolizumab-to-radium-223-in-metastatic-castration-resistant-prostate-cancer
#14
JOURNAL ARTICLE
Atish D Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M Allaire, Jaqueline Marquez, David D Yang, Abhishek Tripathi, Jacqueline M Kilar, Meredith Flynn, Brianna Maynard, Rebecca Reichel, Amanda F Pace, Brandon K Chen, Eliezer M Van Allen, Kerry Kilbridge, Xiao X Wei, Bradley A McGregor, Mark M Pomerantz, Rupal S Bhatt, Christopher J Sweeney, Glenn J Bubley, Heather A Jacene, Mary-Ellen Taplin, Franklin W Huang, Lauren C Harshman, Lawrence Fong
The checkpoint immunotherapeutic pembrolizumab induces responses in a small minority of patients with metastatic castration-resistant prostate cancer (mCRPC). Radium-223 (R223) may increase immunogenicity of bone metastases and increase pembrolizumab (P) activity. In a randomized phase II study, we assessed the effect of R223+P compared with R223 on tumor immune infiltration, safety, and clinical outcomes in patients with mCRPC. The primary endpoint was differences in CD4+ and CD8+ T-cell infiltrate in 8-week versus baseline bone metastasis biopsies; secondary endpoints were safety, radiographic progression-free survival (rPFS), and overall survival (OS)...
March 29, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38526128/the-%C3%AF-3-polyunsaturated-fatty-acid-docosahexaenoic-acid-enhances-nk-cell-antitumor-effector-functions
#15
JOURNAL ARTICLE
Shuting Wu, Hongyan Peng, Songyang Li, Lanlan Huang, Xiangyu Wang, Yana Li, Yongjie Liu, Peiwen Xiong, Qinglan Yang, Kunpeng Tian, Weiru Wu, Rongxi Pu, Xiulan Lu, Zhenghui Xiao, Jian Yang, Zhaoyang Zhong, Yuan Gao, Yafei Deng, Youcai Deng
ω-3 polyunsaturated fatty acids (PUFAs) are known to directly repress tumour development and progression. In this study, we explored whether docosahexaenoic acid (DHA), a type of ω-3 PUFA, had an immunomodulatory role in promoting tumour growth in immunocompetent mice. The number of natural killer (NK) cells but not the number of T or B cells was decreased by DHA supplementation in various tissues under physiological conditions. Although the frequency and number of NK cells were comparable, IFN-γ production by NK cells in both the spleen and lung was increased in DHA-supplemented mice in the mouse B16F10 melanoma tumour model...
March 25, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38517470/an-irf2-expressing-oncolytic-virus-changes-the-susceptibility-of-tumor-cells-to-antitumor-t-cells-and-promotes-tumor-clearance
#16
JOURNAL ARTICLE
Lulu Shao, Rashmi Srivastava, Greg M Delgoffe, Stephen H Thorne, Saumendra N Sarkar
Interferon regulatory factor 1 (IRF1) can promote antitumor immunity. However, we have shown previously that in the tumor cell, IRF1 can promote tumor growth, and IRF1-deficient tumor cells exhibit severely restricted tumor growth in several syngeneic mouse tumor models. Here, we investigate the potential of functionally modulating IRF1 to reduce tumor progression and prolong survival. Using inducible IRF1 expression, we established that it is possible to regulate IRF1 expression to modulate tumor progression in established B16-F10 tumors...
March 22, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38558120/engineering-cd3-cd137-dual-specificity-into-a-dll3-targeted-t-cell-engager-enhances-t-cell-infiltration-and-efficacy-against-small-cell-lung-cancer
#17
JOURNAL ARTICLE
Hirofumi Mikami, Shu Feng, Yutaka Matsuda, Shinya Ishii, Sotaro Naoi, Yumiko Azuma, Hiroaki Nagano, Kentaro Asanuma, Yoko Kayukawa, Toshiaki Tsunenari, Shogo Kamikawaji, Ryutaro Iwabuchi, Junko Shinozuka, Masaki Yamazaki, Haruka Kuroi, Samantha Shu Wen Ho, Siok Wan Gan, Priyanka Chichili, Chai Ling Pang, Chiew Ying Yeo, Shun Shimizu, Naoka Hironiwa, Yasuko Kinoshita, Yuichiro Shimizu, Akihisa Sakamoto, Masaru Muraoka, Noriyuki Takahashi, Tatsuya Kawa, Hirotake Shiraiwa, Futa Mimoto, Kenji Kashima, Mika Kamata-Sakurai, Shumpei Ishikawa, Hiroyuki Aburatani, Takehisa Kitazawa, Tomoyuki Igawa
Small cell lung cancer (SCLC) is an aggressive cancer for which immune checkpoint inhibitors (ICIs) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives for ICI-resistant tumors, but not all SCLC patients are responsive. Herein, to integrate CD137 costimulatory function into a T-cell engager format and thereby augment therapeutic efficacy, we generated a CD3/CD137 dual-specific Fab and engineered a DLL3-targeted trispecific antibody (DLL3 trispecific). The CD3/CD137 dual-specific Fab was generated to competitively bind to CD3 and CD137 to prevent DLL3-independent cross-linking of CD3 and CD137, which could lead to systemic T-cell activation...
March 20, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38489753/the-exonuclease-trex1-constitutes-an-innate-immune-checkpoint-limiting-cgas-sting-mediated-antitumor-immunity
#18
JOURNAL ARTICLE
Junghyun Lim, Ryan Rodriguez, Katherine Williams, John Silva, Alan G Gutierrez, Paul Tyler, Faezzah Baharom, Tao Sun, Eva Lin, Scott Martin, Brandon D Kayser, Robert J Johnston, Ira Mellman, Lélia Delamarre, Nathaniel R West, Sören Müller, Yan Qu, Klaus Heger
The DNA exonuclease TREX1 (Three-prime repair exonuclease 1) is critical for preventing autoimmunity in mice and humans by degrading endogenous cytosolic DNA, which otherwise triggers activation of the innate cGAS/STING pathway leading to the production of type I IFNs. Since tumor cells are prone to aberrant cytosolic DNA accumulation, we hypothesized that they are critically dependent on TREX1 activity to limit their immunogenicity. Here we show, that in tumor cells TREX1 indeed restricts the spontaneous activation of the cGAS/STING pathway and the subsequent induction of a type I IFN response...
March 18, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38437646/chronic-stress-exacerbates-the-immunosuppressive-microenvironment-and-progression-of-gliomas-by-reducing-secretion-of-ccl3
#19
JOURNAL ARTICLE
Xu Wang, Long Zhang, Yi Zhou, Yan Wang, Xiang Wang, Yining Zhang, Ankang Quan, Yufei Mao, Yu Zhang, Ji Qi, Zhongyu Ren, Linbo Gu, Rutong Yu, Xiuping Zhou
As understanding of cancer has deepened, increasing attention has been turned to the roles of psychological factors, especially chronic stress-induced depression, in the occurrence and development of tumors. However, whether and how depression affects the progression of gliomas are still unclear. In this study, we have revealed that chronic stress inhibited the recruitment of tumor-associated macrophages (TAMs) and other immune cells, especially M1-type TAMs and CD8+ T cells, and decreased the level of proinflammatory cytokines in gliomas, leading to an immunosuppressive microenvironment and glioma progression...
March 1, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38408184/intratumoral-trex1-induction-promotes-immune-evasion-by-limiting-type-i-interferon
#20
JOURNAL ARTICLE
Eléonore Toufektchan, Alexandra Dananberg, Josefine Striepen, James H Hickling, Abraham Shim, Yanyang Chen, Ashley Nichols, Mercedes A Duran Paez, Lisa Mohr, Samuel F Bakhoum, John Maciejowski
Chromosomal instability is a hallmark of human cancer that is associated with aggressive disease characteristics. Chromosome mis-segregations help fuel natural selection, but they risk provoking a cGAS-STING immune response through the accumulation of cytosolic DNA. The mechanisms of how tumors benefit from chromosomal instability while mitigating associated risks, such as enhanced immune surveillance, are poorly understood. Here, we identify cGAS-STING-dependent upregulation of the nuclease TREX1 as an adaptive, negative feedback mechanism that promotes immune evasion through digestion of cytosolic DNA...
February 26, 2024: Cancer Immunology Research
journal
journal
47924
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.